Mostrar el registro sencillo del ítem

dc.contributor.authorCordero Choquet de Isla, Javier 
dc.contributor.authorRiscart López, Javier 
dc.contributor.authorSanchez Gomar, Ismael 
dc.contributor.authorBandez Ruiz, Manuel Jesús 
dc.contributor.authorRosety Rodríguez, Ignacio 
dc.contributor.authorBrenes Martín, Francisco
dc.contributor.authorBazán, Nicolás G.
dc.contributor.authorNavarro Quiroz, Elkin
dc.contributor.authorROSETY RODRÍGUEZ, Miguel Ángel 
dc.contributor.authorGeribaldi Doldán, Noelia 
dc.contributor.otherAnatomía y Embriología Humanaes_ES
dc.contributor.otherBiomedicina, Biotecnología y Salud Públicaes_ES
dc.contributor.otherDidáctica de la Educación Física, Plástica y Musicales_ES
dc.contributor.otherMedicinaes_ES
dc.date.accessioned2026-11-16T10:31:44Z
dc.date.available2026-11-16T10:31:44Z
dc.date.issued2026-10-23
dc.identifier.issn2072-6643
dc.identifier.urihttp://hdl.handle.net/10498/40658
dc.description.abstractBackground/Objectives: Although creatine supplementation has a theoretical rationale for neuroprotection, public interest has outpaced available scientific evidence. Alzheimer’s disease (AD), a major and growing global health concern, is among the neurodegenerative diseases proposed to benefit from creatine supplementation. This scoping review systematically maps the existing literature on creatine supplementation for AD to identify gaps that limit translational progress. Methods: Following JBI methodology and PRISMA-ScR guidelines, a search in five electronic databases was conducted for preclinical and clinical studies evaluating creatine interventions in AD. The methodological quality of the studies was appraised using the SYRCLE and NIH tools, respectively. Results: Nine unique studies were included. The preclinical models investigated neuron apoptosis, oxidative stress, neuroinflammation, mitochondrial function, cognitive outcomes, and pathophysiological clearance. Conversely, clinical studies were limited to a pilot trial that suggested preliminary tolerability but could not establish causality. This review identifies six limitations within the current evidence: (1) a reliance on acute or non-transgenic animal models that lack construct validity; (2) a need to address sexual dimorphism; (3) a lack of studies exploring administration routes to bypass the blood–brain barrier; (4) a complete lack of independent randomized controlled trials (RCTs), with all clinical evidence originating from a single research group; (5) an absence of research assessing creatine as a preventive strategy; and (6) a shortage of assessment regarding physical syndromes, such as frailty. Conclusions: The scientific evidence for creatine in AD remains preliminary. Future research should prioritize progressive transgenic models, evaluate noninvasive administration routes, investigate effects on frailty, assess long-term preventive efficacy, account for sex as a variable, and transition to rigorous RCTs.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMDPI (Multidisciplinary Digital Publishing Institute)es_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/es_ES
dc.sourceNutrients, 18(21), 3477.es_ES
dc.subjectageinges_ES
dc.subjectAlzheimer’s diseasees_ES
dc.subjectneurodegenerationes_ES
dc.subjectcreatinees_ES
dc.subjectnutritiones_ES
dc.subjectbioenergeticses_ES
dc.subjectpreclinical modelses_ES
dc.titleA Scoping Review of Creatine Supplementation in Alzheimer’s Disease: Evidence from Preclinical and Clinical Studieses_ES
dc.typejournal articlees_ES
dc.identifier.urlhttps://www.mdpi.com/2072-6643/18/21/3477
dc.rights.accessRightsopen accesses_ES
dc.identifier.doihttps://doi.org/10.3390/nu18213477
dc.type.hasVersionAMes_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

http://creativecommons.org/licenses/by/4.0/
Esta obra está bajo una Licencia Creative Commons http://creativecommons.org/licenses/by/4.0/